SONN Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (23 bal. 2024 @ 23:00):

Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action...

Stats
Šios dienos apimtis	18 191.00
Vidutinė apimtis	103 879
Rinkos kapitalizacija	5.46M
EPS	$0 ( 2024-02-14 )
Kita pelno data	( $0.130 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.14
ATR14	$0.0200 (1.12%)

Insider Trading

Date	Person	Action	Amount	type
2023-10-27	Rao Raghu	Buy	31 250	Warrant to Purchase Common Stock
2023-10-27	Rao Raghu	Buy	15 625	Common Stock
2023-10-27	Mohan Pankaj	Buy	68 750	Warrant to Purchase Common Stock
2023-10-27	Mohan Pankaj	Buy	34 375	Common Stock
2023-08-07	Markey John	Sell	0	Common Stock

INSIDER POWER
82.27
Last 88 transactions
Buy: 5 035 351 \| Sell: 2 861 714

Sonnet Biotherapeutics Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Sonnet Biotherapeutics Koreliacija - Valiuta/Žaliavos

-0.07
( neutral )

0.02
( neutral )

0.00
( neutral )

-0.05
( neutral )

0.32
( neutral )

-0.32
( neutral )

Sonnet Biotherapeutics Finansinės ataskaitos

Annual	2023
Pajamos:	$147 805
Bruto pelnas:	$72 055.00 (48.75 %)
EPS:	$-18.14

Q4	2023
Pajamos:	$37 255.00
Bruto pelnas:	$17 789.00 (47.75 %)
EPS:	$-2.10

Q3	2023
Pajamos:	$36 850.00
Bruto pelnas:	$17 873.00 (48.50 %)
EPS:	$-2.96

Q2	2023
Pajamos:	$36 445.00
Bruto pelnas:	$17 572.00 (48.22 %)
EPS:	$-7.56

Financial Reports:

No articles found.

Sonnet Biotherapeutics

Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.